Forte Biosciences Stock (NASDAQ:FBRX)

Forecast Ownership Financials Chart

Previous Close

$11.23

52W Range

$4.11 - $28.68

50D Avg

$11.23

200D Avg

$11.69

Market Cap

$136.76M

Avg Vol (3M)

$98.24K

Beta

2.91

Div Yield

-

FBRX Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Apr 13, 2017

Website

FBRX Performance

FBRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-36.60M	$-32.49M	$-13.90M
Net Income	$-35.48M	$-31.48M	$-13.86M
EBITDA	$-36.60M	$-32.48M	$-13.90M
Basic EPS	$-12.17	$-24.92	$-19.96
Diluted EPS	$-12.17	$-24.92	$-19.96

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 21May 11, 21 | 4:30 PM

Peer Comparison

Ticker	Company
BYSI	BeyondSpring Inc.
TPST	Tempest Therapeutics, Inc.
VRPX	Virpax Pharmaceuticals, Inc.
GYRE	Gyre Therapeutics, Inc.
IPHA	Innate Pharma S.A.
IKNA	Ikena Oncology, Inc.
RNXT	RenovoRx, Inc.